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Rheumatoid arthritis
AbstrAct
Background Despite the wide array of treatments 
available for rheumatoid arthritis (ra), some patients 
continue to report unmet clinical needs. We investigated 
the extent of inadequate disease control in patients with 
ra.
Methods Data were drawn from the adelphi 2014 ra 
Disease-Specific Program in France, germany, italy, 
Spain and the UK. rheumatologists provided patient 
demographics, comorbidities, satisfaction with ra control 
and other clinical details. Patients reported their level of 
satisfaction and completed the euroQol 5-Dimensions 
Health Questionnaire and Work Productivity and activity 
impairment Questionnaire. Patients had been on their 
current therapy ≥3 months and had 28-joint disease 
activity scores (DaS28) reported. adequately controlled 
(DaS28 ≤3.2) and inadequately controlled (DaS28 >3.2) 
patient cohorts were compared using univariate tests.
Results Of 1147 patients, 74% were women, the mean 
age was 52 years and the mean time since ra diagnosis 
was 7 years. twenty-seven percent of patients had 
inadequately controlled ra, whereas 73% had adequately 
controlled ra. inadequately controlled patients were more 
affected clinically versus adequately controlled patients; 
69% vs 13% had moderate/severe ra, the current level 
of pain was 4.6 vs 2.3, and 67% vs 41% experienced 
flares, respectively (all p<0.0001). inadequately controlled 
patients had higher rates of depression (16% vs 5%; 
p<0.0001), worse health state, greater work and 
activity impairment, and lower satisfaction rates among 
the patients and their physicians than the adequately 
controlled cohort.
Conclusion ra was insufficiently controlled in over a 
quarter of patients despite their current therapy and this 
had a negative impact on the patients.
InTRoduCTIon
Rheumatoid arthritis (RA) is a debilitating 
autoimmune disease affecting up to 1% of 
the world population.1 Progress in the last 
two decades has resulted in an armamen-
tarium of available treatments, the majority 
of which are disease-modifying antirheumatic 
drugs (DMARDs). Current European League 
Against Rheumatism (EULAR) guidelines 
recommend starting therapy with the conven-
tional synthetic DMARD (csDMARD), meth-
otrexate, in combination with short-term 
glucocorticoids.2 If this treatment is not 
successful or methotrexate is contraindicated, 
in the absence of poor prognostic factors, 
other csDMARDS should be considered. The 
guidelines state that if the treatment target is 
not reached with the first csDMARD strategy, 
when poor prognostic factors are present, a 
biologic DMARD (bDMARD) should be added 
(current practice). Unlike the 2014 EULAR 
guidelines,3 the 2016 EULAR guidelines have 
expanded this recommendation to include 
targeted synthetic DMARDs (tsDMARDs), 
specifically Janus kinase (JAK) inhibitors, as 
second-line options (currently tofacitinib 
and baricitinib). The American College of 
Rheumatology (ACR) guidelines recommend 
treatment strategies based on disease activity, 
Key messages
What is already known about this subject?
 ► Despite the availability of numerous treatments for 
rheumatoid arthritis (ra), some patients continue to 
experience pain, impaired physical/mental function 
and fatigue.
What does this study add?
 ► this study demonstrates the extent of unmet 
clinical needs associated with both adequate and 
inadequate disease control in patients with ra.
How might this impact on clinical practice?
 ► these findings highlight the need to assess 
patients’ physical and mental well-being alongside 
clinical measures of disease activity and may help 
to guide treatment decisions.
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as well as differentiating between early RA, established RA 
and high-risk comorbidities.4 When using disease activity 
scores for 28 joints (DAS28), ACR defined remission 
as <2.6, low disease activity as ≥2.6–<3.2, moderate disease 
activity as ≥3.2–≤5.1 and high disease activity as >5.1. For 
moderate to high disease activity, ACR recommendations 
are similar to the EULAR recommendations but offer 
the choice of combination csDMARD therapy or adding 
a tumour necrosis factor inhibitor (TNFi) or non-TNFi 
biologic or tofacitinib if disease activity remains moderate 
or high despite csDMARD monotherapy.4 
The phenotype and disease course of RA has evolved 
over the last two generations,5–7 such that fewer patients 
have severely deforming disease at presentation (due to 
a shorter referral time and early diagnosis) or very high 
acute phase responses, fewer patients develop severely 
deforming disease and severe comorbidities are less 
common. Despite moderate to severe levels of disease 
activity by composite scores, the majority of patients no 
longer exhibit progressive structural damage to joints. 
These changes are possibly due to earlier and more 
optimal use of DMARDs and/or environmental changes, 
which may have led to tighter control of RA. However, 
up to 30% of patients have an inadequate response or 
intolerance to methotrexate or have an inadequate 
response or loss of response to bDMARDs.8 9 Addition-
ally, despite the wide array of available treatments for RA, 
there are unmet clinical needs across key domains such 
as pain, physical function, mental function and fatigue, 
which can affect social function, sexual function and the 
ability to work.10–13 Indeed, in the established phase of 
disease, real-world data show that remission, particularly 
as assessed by more stringent criteria such as the Clin-
ical Disease Activity Index or the EULAR/ACR Boolean 
criteria, remains a largely aspirational goal.14–16 Current 
EULAR guidelines recommend targeting sustained 
remission or low disease activity for the management of 
RA as well as shared decision-making between rheumatol-
ogists and their patients.3
In order to understand the scope of unmet needs in 
RA, we examined the extent of inadequately controlled 
RA and the accompanying clinical and contextual char-
acteristics in patients in five European countries.
MeTHods
study design
This was an analysis of cross-sectional data drawn from 
the Adelphi RA Disease Specific Programme (DSP), a 
survey of rheumatologists and their consulting patients 
with RA. A DSP is a survey conducted to provide impartial 
observations of real-world clinical practice from a physi-
cian and matched patient viewpoint, irrespective of what 
guidelines are advocated. The DSP is not run to test any 
specific hypotheses, and it is not set up to demonstrate 
cause and effect, but is designed to provide a holistic, 
benchmark view of contemporary RA management via 
physician-reported and patient-reported measures.17 The 
survey was conducted in France, Germany, Italy, Spain 
and the UK from January 2014 to August 2014.
Physicians and patients
Physicians had to have seen more than eight patients with 
RA in a typical month, to have qualified as a physician 
between 1975 and 2010 and be actively involved in the 
management of RA to be eligible for inclusion. Physicians 
provided treatment histories for all patients, including 
use of csDMARDs, bDMARDs or other RA treatments 
(cyclo-oxygenase-2 (COX-2) inhibitors, non-steroidal 
anti-inflammatory drugs other than COX-2 inhibitors, 
non-opioid analgesics, opioid analgesics, oral steroids, 
locally injected steroids and gastroprotective agents). The 
sequence of bDMARD treatments received and reasons 
for not prescribing a bDMARD were also given, if appli-
cable. Assessment of the disease severity (mild, moderate 
and severe) of patients with RA or of remission was based 
on the physician’s own perception of the disease status. 
Patients with a diagnosis of RA, aged ≥18 years and not 
currently in a clinical trial were eligible for inclusion in 
the DSP.
data collection
Physicians were identified by the local fieldwork teams 
from public lists of rheumatologists. Candidate respond-
ents who met the eligibility criteria were subsequently 
invited to participate in the DSP and were compensated 
to participate in this research according to fair market 
research rates consistent with the time involved. Partic-
ipating physicians included the first eight consecutive 
patients who met the eligibility criteria in the survey. 
As the methodology required consecutively presenting 
patients with RA for each physician, the DSP sample is 
representative of the consulting population.
Physicians completed a detailed physician record form 
(PRF) on each patient who met the recruitment criteria. 
The PRF contained detailed questions on patient demo-
graphics, diagnoses, severity of condition and specific 
symptoms, acute episodes/flares, concomitant conditions, 
current treatment, drivers of therapy choice, compliance 
and general patient management (such as frequency of 
consultation with the treating and other physicians). Each 
patient with a completed PRF was invited to complete a 
patient self-completion (PSC) form; on agreement, these 
patients provided written informed consent for partic-
ipation in the survey and use of their anonymised and 
aggregated data for research and publication in scientific 
journals. Patients completed their PSCs independently 
of their physician and returned them in a sealed enve-
lope to ensure that responses were kept confidential 
from physicians. PSCs contained detailed questions on 
demographics, the patient’s current condition, level of 
satisfaction with their treatment, and compliance. PSCs 
also included validated quality of life instruments; the 
EuroQoL 5-Dimensions (EQ-5D) health questionnaire18 
was used to assess the emotional and physical impact of 
RA, while the Work Productivity and Activity Impairment 
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(WPAI) questionnaire19 assessed the impact on func-
tioning. Patients could choose not to complete the PSC; 
however, each completed PSC could be matched to the 
physician-reported information on that patient.
A complete description of the methods of the survey 
has been previously published and validated.17 20 21 Using 
a check box, patients provided informed consent for use 
of their anonymised and aggregated data for research and 
publication in scientific journals. Data were collected in 
such a way that patients and physicians could not be iden-
tified directly; all data were aggregated and de-identified 
before receipt. Data collection was undertaken in line 
with European Pharmaceutical Marketing Research Asso-
ciation guidelines22 and as such it does not require ethics 
committee approval. The survey was performed in full 
accordance with relevant legislation at the time of data 
collection, including the Health Information Technology 
for Economic and Clinical Health Act legislation.23
statistical analysis
Two patient cohorts were created based on the 
physician-reported DAS28: adequately controlled 
(DAS28 ≤3.2) and inadequately controlled (DAS28 >3.2). 
DAS28 was calculated by the physician when the patient 
was visiting them (thus the PGA was available and used 
in the calculation), and later reported by the physician 
in the PRF. Patients without a DAS28 score provided by 
their rheumatologist and those who had not been on 
their current therapy for ≥3 months were excluded from 
this analysis. Descriptive statistics were used to describe 
the two cohorts and statistical differences between the 
cohorts were assessed using Mann-Whitney U tests for 
numerical outcomes and Fisher exact tests for categorical 
data. Missing data were not imputed. Any patients with 
missing values for a particular variable were removed for 
all analyses where that variable was used, but remained 
eligible for inclusion in other analysis.
ResulTs
A total of 307 rheumatologists provided data for 2536 
patients (France n=502; Germany n=491; Italy n=501; 
Spain n=486; UK n=556). Of these, 1147 PRFs and 337 
PSCs were available for analysis in this study (figure 1). 
The remaining 1389 PRFs were not available for analysis 
as described in figure 1. A majority of the patients were 
women (74%), the mean age was 52 years, the mean time 
since RA diagnosis was 7 years and 76% were reported to 
be positive for anticyclic citrullinated peptide antibodies 
by their rheumatologist at their most recent assessment 
(table 1). All patients who had ever received bDMARDs 
were receiving bDMARDs at the time of the survey.
Approximately a quarter of the patients (27%, 
308/1147) had inadequately controlled RA compared 
with 73% (839/1147) who had adequately controlled RA. 
As shown in table 1, the inadequately controlled cohort 
had more patients with moderate/severe RA than those 
with adequately controlled RA (69% vs 13%, respectively; 
p<0.0001) and fewer patients with stable disease status 
(38% vs 65%; p<0.0001). Further analyses revealed that 
mean DAS28 scores associated with mild, moderate and 
severe disease status were 2.47, 3.67 and 5.02, respectively.
Patients in the inadequately controlled cohort had 
a higher level of pain compared with the adequately 
controlled cohort (4.6 vs 2.3; p<0.0001), were more likely 
to ever have experienced flares (67% vs 41%; p<0.0001) 
and had higher rates of depression (16% vs 5%; 
p<0.0001). Of note, 14% of patients in the inadequately 
controlled cohort were considered to be in remission by 
their physician despite their DAS28 score being >3.2.
A difference in quality of life was also observed between 
the two cohorts, with a mean EQ-5D of 0.53 for the inad-
equately controlled patients compared with 0.77 for the 
adequately controlled patients (p<0.0001; figure 2A). As 
would be expected, the WPAI scores indicated greater 
Figure 1 Flow of participants. DAS28, disease activity score in 28 joints; PRF, patient record form; PSC, patient self-
completion form.
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work and activity impairment in the inadequately 
controlled patients than in the adequately controlled 
cohort; however, some impairment also persisted in the 
adequately controlled cohort (figure 2B).
Fewer physicians were satisfied with control of RA in 
the inadequately controlled patient group compared with 
the adequately controlled group (31% vs 88%, respec-
tively; p<0.0001; figure 3A), and this was mirrored by 
the satisfaction levels reported by patients (55% vs 85%, 
respectively; p<0.0001; figure 3B). Interestingly, even in 
the adequately controlled cohort, 7% of physicians and 
12% of patients stated that they were dissatisfied with the 
level of RA control but thought it was the best possible, 
while 5% of physicians and 3% of patients were dissatis-
fied but thought it would be possible to achieve better 
RA control.











Age (years), mean (SD) 51.6 (13.7) 53.0 (13.7) 51.1 (13.7) 0.0366 (MW)
Gender (female), n (%) 851 (74) 230 (75) 621 (74) 0.8790 (FE)
BMI (kg/m2), mean (SD) 25.2 (4.4) 25.8 (4.8) 24.9 (4.2) 0.0038 (MW)
Positive for anticyclic citrullinated peptide 
antibodies, n (%)
670 (76) 184 (78) 486 (75) 0.3763 (FE)
Most recent ESR (mm/hour), mean (SD) 18.2 (14.3) 26.6 (17.2) 15.2 (11.8) <0.0001 (MW)
Most recent CRP (mg/L), mean (SD) 5.4 (4.7) 7.5 (6.4) 4.7 (3.7) <0.0001 (MW)
RF positive, n (%) 775 (82) 211 (81) 564 (83) 0.4489 (FE)
Time since diagnosis (years), mean (SD) 7.0 (6.8) 7.1 (6.9) 7.0 (6.8) 0.8961 (MW)
Currently in remission, n (%) 614 (54) 42 (14) 572 (68) <0.0001 (FE)
Current severity, n (%) < 0.0001  (MW) 
  Mild 829 (72) 96 (31) 733 (87) 
  Moderate 279 (24) 179 (58) 100 (12) 
  Severe 39 (3) 33 (11) 6 (1) 
Current disease status, n (%) < 0.0001 (MW) 
  Improving 327 (29) 67 (22) 260 (31) 
  Stable 661 (58) 116 (38) 545 (65) 
  Deteriorating slowly 97 (9) 78 (26) 19 (2) 
  Deteriorating rapidly 22 (2) 21 (7) 1 (0.1) 
  Unstable 31 (3) 21 (7) 10 (1) 
Current level of pain (1=none; 10=worst), 
mean (SD)
2.9 (1.8) 4.6 (1.9) 2.3 (1.2) <0.0001 (MW)
Patients who had ever experienced 
flares*, n (%)
550 (48) 204 (67) 346 (41) <0.0001 (FE)
Comorbidities, n (%)†
  Depression 93 (8) 48 (16) 45 (5) <0.0001 (FE)
  None 584 (51) 107 (35) 477 (57) <0.0001 (FE)
Ever received bDMARD, n (%) 526 (46) 157 (51) 369 (44) 0.0382 (FE) 
Current/most recent bDMARD, n (%) 0.0178 (PC) 
  TNF inhibitor 344 (65) 91 (58) 253 (69) 
  Non-TNF inhibitor 182 (35) 66 (42) 116 (31) 
  Missing 621 151 470 
*Based on the physician’s own definition of flare.
†Only those that were significantly different between the two groups are listed.
bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score in 
28 joints; ESR, erythrocyte sedimentation rate; FE, Fisher exact; MW, Mann-Whitney; PC, Pearson’s χ2; RF, rheumatoid factor; TNF, tumour 
necrosis factor.
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dIsCussIon
This cross-sectional study was performed to define key 
‘real-world’ unmet needs in the treatment of patients 
with RA in the era of bDMARDs, by identifying areas 
where guideline-defined aspirations and the realities of 
patient experiences and clinical practice do not match. 
The study showed that almost a quarter of patients with 
RA have insufficiently controlled disease (DAS28 >3.2) 
despite current therapy, which could be related to the 
long average duration of disease (7 years). Our findings 
are consistent with other reports from observational 
studies. For example, in 2013, based on standardised 
monitoring of patients in an ordinary outpatient clinic 
in southern Norway, 26.6% of patients had DAS28 >3.2.24
Even though patients with inadequately controlled RA 
are more affected clinically, more impacted in their daily 
lives and less satisfied overall, in some cases physicians 
may perceive these patients to be adequately controlled. 
This was demonstrated in this study as 14% of physicians 
reported that patients were in remission despite sepa-
rately reporting DAS28 >3.2 scores, that is, in the inade-
quate control cohort. In the PRF, the physician was asked 
if the patient was currently in remission in one section, 
without any guidance that the response should be based 
on any particular criteria. The physician was asked to 
report the DAS28 score as assessed at the consultation 
in a separate section, thus it is quite likely that physicians 
reported a subjective view for the question about remis-
sion, which resulted in discordance between disease status 
and DAS28 score. Similar differences in physician-re-
ported and DAS28-based assessment of disease remission 
have been reported previously among patients with RA 
in clinical practices in the USA, with physicians subjec-
tively reporting that 50% of patients were in remission 
although only 32% were in remission by DAS28 criteria.25 
Physicians may also have considered a patient to have 
achieved the lowest level of disease activity attainable by 
that individual, as demonstrated in this study by physi-
cians reporting that they were dissatisfied with RA control 
in 28% of patients with inadequate control by DAS28, 
but that this was the best possible in those patients. The 
discordance between physician perception and DAS28 
scores may also have been driven by the number of 
bDMARDs received by some patients, with patients who 
had received more bDMARDs being perceived to have 
attained the best control possible. Consequently, discor-
dance between physicians’ perceptions and the objec-
tive DAS28 may result in less than optimal therapeutic 
management in some patients. In this study, over half of 
patients with inadequately controlled disease reported 
being satisfied with the control that their RA therapy 
provided, suggesting that they too may be accepting 
Figure 2 Patient-reported outcomes. (A) EQ-5D (B) WPAI. P values were calculated using the Mann-Whitney U test. DAS28, 
disease activity score in 28 joints; EQ-5D, EuroQoL 5-Dimensions; WPAI, Work Productivity and Activity Impairment.
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suboptimal outcomes. A study on the degree of discor-
dance between patient and physician assessment of RA 
severity reported that nearly a third of patients differed 
from their physicians, with physicians recording less 
severe disease compared with the patients.26 The same 
study also highlighted that greater depressive symptoms 
in patients were associated with discordance in patient-re-
ported versus physician-reported RA severity measured 
by DAS28 scores. High rates of depression were also 
reported in patients with inadequately controlled RA in 
the current study.
In terms of limitations, this study was performed in 
Germany, Spain, France, Italy and the UK, all of which 
are countries with relatively advanced healthcare systems 
and broad access to treatment and disease management 
programmes, although access to bDMARDs is restricted 
to patients with DAS28 >5.1 in the UK. Generalisation 
of this study’s findings beyond these countries warrants 
caution; there is a discrepancy in access to treatment/
early diagnosis, patient perceptions are different in more 
affluent countries, cost often restricts access to the full 
range of available treatments, and subsets of patients can 
have reduced access.27–29 Additionally, the sample is not 
entirely representative of the practising population of 
rheumatologists (the physicians participating in the DSP 
will be skewed towards those with a higher workload due 
to the screening criteria) and infrequently consulting 
patients may be under-represented due to the sampling 
approach. There could also be an element of measure-
ment bias in some of the responses provided by the physi-
cian/patient; however, they have to be relied on to provide 
the most accurate information possible. Furthermore, 
data for a large number of patients (1160/2536) could 
not be included because of failure to record DAS28. In a 
further 229 patients, PRF forms were not included as treat-
ment duration was either not available or was not consid-
ered sufficiently long for it to be effective (figure 1). In 
relation to this, results from the CAPEA study indicated 
Figure 3 Satisfaction with control of RA. (A) Physician-reported satisfaction, (B) Patient-reported satisfaction. p values were 
calculated using the Mann-Whitney U test. DAS28, disease activity score in 28 joints; RA, rheumatoid arthritis.
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that treatment was not changed in response to disease 
activity in 60% of the patients who did not reach remis-
sion within 3 months and 54% of patients who did not 
reach remission by 6 months.30 Taken together, these 
studies reflect a common limitation of current practice 
and suggest that further training on the role of DAS28 is 
needed for rheumatologists, to reinforce the importance 
of using objective measures of disease to make informed 
treatment decisions for patients with RA.
The nature of unmet needs in RA has changed over 
the last few decades; although the mean disease activity 
may be lower than before, psychological and other 
aspects that affect patients’ well-being, such as depres-
sion, fatigue and comorbidities, constitute contem-
porary unmet needs that should be addressed with a 
multidisciplinary approach.31–33 In this context, a struc-
tured literature review from 2004 to 2014 identified 
that patients continued to experience pain, morning 
stiffness, physical disability, mental health problems and 
unacceptable levels of fatigue despite ongoing treat-
ment.13 A large longitudinal study carried out over 8 
years also demonstrated recently that improved treat-
ment strategies did not result in less severe fatigue in 
patients with RA.34 Experts at the Targeted Therapies 
2016 meeting acknowledged the progress in treatment 
of RA but recognised that a significant proportion of 
patients continued to suffer with moderate to high RA, 
despite ongoing treatment and adoption of a treat to 
target strategy.35 Identification of patients in remission 
who would be candidates for dose reduction and devel-
opment of biomarkers or imaging programmes to iden-
tify these patients, as well as development of therapeutics 
that could repair the damage caused by RA or increase 
remission rates, were also identified as current unmet 
needs in RA.35 Of note, there is increasing focus on 
involving patients in the decision-making process from 
an early stage as this has been associated with higher 
patient satisfaction with care,36 and the hope is that 
increased communication between patients and physi-
cians will enable amelioration of these remaining unmet 
needs in RA. DMARDs that meet patient preferences, for 
example, the route of administration or monotherapy 
versus combination therapy with methotrexate, may 
increase compliance and adherence.37 Furthermore, 
new drugs currently being developed and tested, such 
as small molecule tsDMARDs, may improve the efficacy 
of treatment in patients who are non-responsive or intol-
erant to the currently available RA treatments.38 39
ConClusIons
This study documents the continued existence of unmet 
needs in patients with RA, despite the advances in treat-
ments and strategies. These unmet needs exist not only 
for the inadequately controlled patients (DAS28 >3.2), as 
might be expected, but also, to a lesser extent, for those 
considered to be adequately controlled (DAS28 ≤3.2). 
This may be associated with discordance between 
patients’ and physicians’ perceptions of RA severity as 
well as a lack of shared decision-making.
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